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Purpose: To evaluate the effectiveness of oxygen nebulization at preventing radiotherapy-
induced mucositis in patients with nasopharyngeal cancer.
Methods: Sixty patients with nasopharyngeal cancer treated with simultaneous integrated
boost intensity-modulated radiotherapy were randomly assigned to oxygen nebulization or
ultrasonic nebulization groups; treatment was once daily for 20 minutes. All patients
received routine oral care. We compared saliva pH and volume, food intake, and change in
oral mucosa during radiotherapy, and dry mouth and sore throat after radiotherapy be-
tween the two groups.
Results: There were significant differences in the incidence of grade III or IV mucositis,
saliva volume and pH, and dry mouth and sore throat between the two groups when the
total dose was 33 Gy (p < 0.05 or p < 0.01).
Conclusion: Oxygen nebulization reduces radiotherapy-induced mucositis and relieves
symptoms such as dry mouth and sore throat in patients with nasopharyngeal cancer.
Copyright ª 2014, Chinese Nursing Association. Production and hosting by Elsevier
(Singapore) Pte Ltd. All rights reserved.1. Introduction
Radiotherapy remains the preferred treatment for nasopha-
ryngeal cancer; the most common adverse reaction is acute
oral mucosa reaction to radiotherapy. The reaction ism (J. Xu).
Nursing Association
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g Association. Productioncharacterized by dry mouth, oropharyngeal pain, oral
inflammation, pseudomembrane formation, easily broken
mucous membranes, bleeding, ulcer formation, and eating
disorder, All of which has a serious influence on radiotherapy,
even leading to its suspension. Therefore, preventing and
controlling oral mucosa reaction to radiotherapy effectively isand hosting by Elsevier (Singapore) Pte Ltd. All rights reserved.
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tion is used for patients with chronic obstructive pulmonary
disease [1] and infantile acute laryngitis [2], but its effect in the
treatment of oral mucosa reaction to radiotherapy is un-
known; therefore, we examined the effect of oxygen nebuli-
zation therapy in patients with nasopharyngeal cancer during
radiotherapy in this study.2. Design and methods
2.1. Participants
Between December 2011 and December 2012, we enrolled 60
patients with a pathological diagnosis of nasopharyngeal
cancer at our department, and assigned them to experimental
(n ¼ 30) and control (n ¼ 30) groups using the random number
table method. Inclusion criteria: (1) pathological diagnosis of
nasopharyngeal; (2) received radiotherapy for the first time; (3)
Karnofsky functional status score  70 points; (4) no oral
mucosal inflammation, cavities, dentures, or other oral dis-
eases; (5) no synchronous chemotherapy or radiotherapy
sensitization agent use during radiotherapy; (6) adherence to
treatment as required. The grouping method was as follows:
we obtained 60 random numbers with the random number
table, removed the same numbers, and then assigned these
random numbers to patients according to time of hospital
admission. We ranked the numbers from small to large and
placed the first 30 in the experimental group; the remaining
numbers were placed in the control group. Table 1 lists the
characteristics of the two groups in terms of age, sex, and
dose. All patients completed the whole research process.
2.2. Methods
2.2.1. Radiotherapy
All subjects were treated with simultaneous integrated boost
intensity-modulated radiotherapy (SIB-IMRT). SIB-IMRT uses
6-MV X-ray, 2.2-Gy gross tumor volume (GTV) dose (visible
tumor imaging and neck lymph node metastasis), 2.0-Gy
clinical target volume (CTV) 1 dose (high-risk areas), and 1.8-
Gy CTV2 dose (low-risk areas) each time for a total 30 times,
and GTV dose to test dose of 66 Gy five times per week.
2.2.2. Nursing intervention
Patients in the experimental group received oral care every
day to maintain oral health, rinsed their mouths daily before
and after radiotherapy and after eating, and received oxygen
nebulization after radiotherapy each day. The drugs used
were 10 mL saline, 240,000 U gentamicin, 4000 UTable 1 e Demographic variables (X ± s).
Group n Age (y) Sex Dose (Gy)
Male Female
Experimental 30 51.43  10.43 21 9 67.61  1.52
Control 30 52.30  10.39 19 11 68.35  2.00
t or c2 0.32 0.30 1.60
p 0.75 0.58 0.11chymotrypsin, and 5mg dexamethasone, with an oxygen flow
rate of 8 L/min for 20 min per session, until the end of radio-
therapy. The control group received the same oral care during
radiotherapy as the experimental group. During radiotherapy,
control group patients received ultrasonic nebulization at the
end of radiotherapy daily, using the same drugs as the
experimental group for 20 min per session.
2.2.3. Outcome measures
Before radiotherapy, three primary nurses were trained to
evaluate the effects. After radiotherapy was administered at
10 AM every Monday, the nurses in charge performed the
following: (1) Oral pH measurement using precise test paper
(Xingxia Xiangrui Technology Development, Beijing) and
measuring the average of two points: the center of the tongue
and on one side of the tongue. (2) Saliva collection using an
Azov mong Trading (Shanghai) triangle funnel; patients
gargled with water before saliva collection, then chewed two
sticks of blueberry-flavored chewing gum for five minutes
without swallowing while chewing. After the chewing gum
had been spat out, the triangle funnel was affixed to the pa-
tient’s jaw, and the patient lowered their head, allowing all of
the saliva collected in their mouth to flow out; bubbles were
filtered out. (3) Observed oral mucosa injury in patients. Based
on the World Health Organization classification [3], radioac-
tive oral mucosa injury was graded 0eIV. Grade 0: no mucosal
response; grade I: mucosal hyperemia; grade II: mottled
mucositis; grade III: 50% flaky mucositis in 50% of the area
exposed to radiotherapy, or with obvious pain; grade IV, flaky
mucositis accounting for >50% of the exposure area or severe
reaction þ need to stop treatment or stopping oral nutrition.
(4) Evaluated dry mouth and degree of oropharyngeal pain
using the visual analog scale ruler [4]. The ruler is numbered
0e10; patients rate their own discomfort: 0: no symptoms,
1e4: mild discomfort, 5e7: medium discomfort, 8e10: severe
dry mouth or oropharyngeal pain.
2.2.4. Statistical analysis
We used SAS 9.0 for statistical analysis. We compared the oral
mucosa reaction between the two groups with nonparametric
tests; oral pH, saliva, and nebulization comfort of the two
groups were compared by t-test.3. Results
3.1. Comparison of oral mucosa reaction
Compared to the control group, significantly fewer patients in
the experimental group had grade IIIeIV mucosal reaction
after receiving up to 33 Gy radiotherapy, at the end of radio-
therapy, and the following one week (p < 0.05, Table 2). As no
patient in either group developed grade 0 or IV reaction, we
merged grade 0 and I, and grade III and IV reactions to reduce
statistical error during statistical analysis.
3.2. Comparison of oral pH and salivary flow rate
Salivary flow rate and pH of the experimental group remained
higher than that of the control group (p < 0.05, Table 3).
Table 2 e Comparison of oral mucosa reaction by grade.
Group n 33-Gy radiotherapy End of radiotherapy One week after end of radiotherapy
0eI II IIIeIV 0eI II IIIeIV 0eI II IIIeIV
Experimental 30 21 6 3 8 12 10 11 11 8
Control 30 12 11 7 1 7 22 2 7 21
ccmh
2 4.86 11.03 12.61
p 0.028 <0.001 <0.001
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at the end of radiotherapy
Oxygen nebulization drug therapy was better than ultrasonic
nebulization in preventing radiation-induced oral mucositis,
dry mouth, sore throat, and other clinical reactions (p < 0.05,
Table 4).4. Discussion
4.1. Analysis of the causes of adverse reactions caused
by oral cavity radiotherapy
At present, radiotherapy is the first choice for treating
nasopharyngeal carcinoma. Oral mucosa reaction to radio-
therapy is one of the most common complications in patients
with nasopharyngeal carcinoma. The oral environment is
moist and rich in blood supply, and the stratified squamous
epithelium, which renews itself quickly, is highly sensitive to
radiation. Salivary gland (parotid, submandibular, sublingual)
secretion decreases after radiotherapy, and saliva decreases,
which causes the oral pH to decrease, leading to dry mouth
and disorder of the oral microenvironment. At the same time,
radiation can damage the mucosa directly, narrowing or
blocking the local microcirculatory vasculature, resulting in
mucosal hyperemia and edema, causing ischemia and hyp-
oxia and causing the oral mucosa reaction to radiotherapy.
Currently, the first choice for treating nasopharyngeal carci-
noma is typically IMRT technology. A clinical randomized
controlled phase III study confirmed the protective effect of
IMRT on parotid gland function [5]; however, it is difficult to
avoid radiation damage to the gland. SIB-IMRT increases
radiotherapy efficacy; at the same time, the increased
radiotherapy dose exacerbates the oral mucosa reaction.
Urgent measures are required to alleviate acute mucosal re-
actions in patients and improve patient tolerance of radio-
therapy. The flow rate of the salivary gland is related to the
average radiation dose: the tolerance dose of the minor
salivary glands is 10e15 Gy. When the major salivary glandsTable 3 e Comparison of oral pH and salivary flow rate (X ± s).
Group n 33-Gy radiotherapy End o
pH Saliva (mL/5 min) pH
Experimental 30 6.25  0.50 3.61  1.01 5.29  0.42
Control 30 5.83  0.43 2.73  1.10 4.85  0.47
t 3.45 3.22 3.84
p 0.001 0.002 <0.001receive the average dose of 20e40 Gy, their function will
gradually decline, and if the average dose exceeds 40 Gy, the
major salivary gland function will decrease dramatically
(>75% loss) [6]. Gland secretions decrease following radio-
therapy mainly because of gland cell apoptosis, decreased
cell numbers, and reduced secretory function. Normal sali-
vary gland secretion is about 0.5 mL/min. Parotid and sub-
mandibular gland secretion respectively account for 60e65%
and 20e30% of salivary gland secretions; gland damage cau-
ses dry mouth. This study also showed that during radio-
therapy, the oral pH and salivary flow rate in patients
decrease when the radiation dose increases; despite the drug
inhalation treatment methods, the patients developed oral
mucositis, dry mouth, and oropharyngeal pain, which is
consistent with the current literature [7]. Preventing oral
mucosa reaction to radiotherapy effectively and relieving dry
mouth and sore throat or other discomfort is a clinical
problem urgently requiring resolution.4.2. Oxygen nebulization can prevent or reduce oral
mucosa reaction to radiotherapy, dry mouth, and sore
throat
Rodriguez et al. found that severe hypoxia was a key factor
in wound non-healing, where hypoxic conditions impede
many aspects of the wound healing process, such as angio-
genesis, fibroblast proliferation, and inflammatory reaction
[8]. Balin and Prantt proved that there is obvious oxygen
toxicity when oxygen pressure >137 mmHg
(1 mmHg ¼ 0.133 kPa), where the oxygen tension for skin
fiber propagation should not exceed 137 mmHg; appropriate
supplemental oxygen improves local microcirculation and
promotes oral mucosal cell proliferation [9]. Oxygen inhibits
bacteria, and the inhibitory effect is divided into specific and
nonspecific suppression. Specific inhibitory effects mainly
inhibit anaerobic bacteria by increasing the oxygen pressure
around the wound; it inhibits bacterial growth by causing
bacterial metabolic disorder. Nonspecific inhibition in-
activates bacterial enzymes, leading to bacterial metabolic
disorder and inhibiting microbial growth. Oxygenf radiotherapy One week after end of radiotherapy
Saliva (mL/5 min) pH Saliva (mL/5 min)
1.53  0.97 6.30  0.43 5.22  0.51
0.97  0.56 5.85  0.44 4.61  0.59
2.77 3.93 4.35
0.008 <0.001 <0.001
Table 4 e Comparison of dry mouth and oropharyngeal
pain at the end of radiotherapy (X ± s).
Group n Dry mouth Oropharyngeal pain
Experimental 30 5.23  1.85 5.40  1.83
Control 30 6.87  1.87 7.17  1.97
t 3.40 3.60
p 0.001 <0.001
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improving local mucosal oxygen pressure and local tissue
oxygen supply during treatment and promoting oral mucosa
healing by improving tissue hypoxia [6], promoting angio-
genesis and achieving anti-inflammatory effects [10]. At the
same time, it increases effective control of local inflamma-
tion, promoting resolution of inflammation and improving
local blood circulation; it also reduces pain and relieves or
dissipates subjective pain.
This study showed that compared to the control group,
the experimental group, which received oxygen nebulization
treatment instead of ultrasonic nebulization during radio-
therapy, experienced oral mucositis, dry mouth, and sore
throat to a lesser degree. During radiotherapy, salivary gland
secretion in both groups decreased when the radiation dose
was increased, and the salivary flow rate decreased. How-
ever, salivary flow rate and pH of the experimental group
remained higher than that of the control group. According to
our analysis, oxygen nebulization drug therapy was better
than ultrasonic nebulization in preventing radiation-induced
oral mucositis, dry mouth, sore throat, and other clinical
reactions. However, further research into an effective
method of preventing oral mucosa reaction or other
discomfort during radiotherapy in patients with nasopha-
ryngeal carcinoma is still required to alleviate patient
discomfort, which would translate into better acceptance of
treatment.Conflicts of interest statement
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